Bio-Techne Announces Exosome Diagnostics Divestiture
Bio-Techne(US:TECH) Prnewswire·2025-08-05 20:30MINNEAPOLIS, Aug. 5, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement where Mdxhealth SA will acquire its Exosome Diagnostics Inc. business, including the ExoDx Prostate (EPI) test, CLIA-certified clinical laboratory and related assets. Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar."Mdxhealth is the ideal acquirer of our ExoDx Prostate test and CLIA-certified laboratory," ...